These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 26769867)
41. Florbetapir-PET imaging and postmortem beta-amyloid pathology. Carome M; Wolfe S JAMA; 2011 May; 305(18):1857; author reply 1857-8. PubMed ID: 21558513 [No Abstract] [Full Text] [Related]
42. Assessment and approval of medical devices used in diagnostic imaging in the United States. Johnson GC Isr J Med Sci; 1986; 22(7-8):505-18. PubMed ID: 3536797 [TBL] [Abstract][Full Text] [Related]
43. Fast high performance liquid chromatography in PET quality control and metabolite analysis. Passchier J Q J Nucl Med Mol Imaging; 2009 Aug; 53(4):411-6. PubMed ID: 19834451 [TBL] [Abstract][Full Text] [Related]
46. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications. DiMasi JA Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388 [TBL] [Abstract][Full Text] [Related]
47. FDA involvement in PET: help or hindrance? Part II. Kotz D J Nucl Med; 1997 Feb; 38(2):9N-11N, 19N. PubMed ID: 9025726 [No Abstract] [Full Text] [Related]
48. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring. Food and Drug Administration, HHS. Final rule. Fed Regist; 1999 May; 64(94):26657-70. PubMed ID: 10558516 [TBL] [Abstract][Full Text] [Related]
49. Regulatory Requirements for PET Drug Production. Schwarz SW; Dick D; VanBrocklin HF; Hoffman JM J Nucl Med; 2014 Jul; 55(7):1132-7. PubMed ID: 24914057 [TBL] [Abstract][Full Text] [Related]
50. Operational radiation safety for PET-CT, SPECT-CT, and cyclotron facilities. Zanzonico P; Dauer L; St Germain J Health Phys; 2008 Nov; 95(5):554-70. PubMed ID: 18849690 [TBL] [Abstract][Full Text] [Related]
51. The Medical Imaging & Technology Alliance conference on research endpoints appropriate for Medicare coverage of new PET radiopharmaceuticals. Hillman BJ; Frank RA; Abraham BC J Nucl Med; 2013 Sep; 54(9):1675-9. PubMed ID: 23907756 [TBL] [Abstract][Full Text] [Related]
52. Nuclear medicine wins decision in FDA PET case. Nichols D J Nucl Med; 1997 Dec; 38(12):23N. PubMed ID: 9430453 [No Abstract] [Full Text] [Related]
53. Enantiopure bifunctional chelators for copper radiopharmaceuticals--does chirality matter in radiotracer design? Singh AN; Dakanali M; Hao G; Ramezani S; Kumar A; Sun X Eur J Med Chem; 2014 Jun; 80():308-15. PubMed ID: 24793881 [TBL] [Abstract][Full Text] [Related]
54. Federal regulations and reimbursement for PET. Keppler JS J Nucl Med Technol; 2001 Dec; 29(4):173-9; quiz 180-2. PubMed ID: 11756528 [TBL] [Abstract][Full Text] [Related]